A groundbreaking national clinical trial backed by the National Institute for Health and Care Research aims to dramatically accelerate the search for effective treatments for Alzheimer’s disease, potentially cutting years from traditional drug development timelines.
The study, known as AD-SMART (Alzheimer’s Disease Systematic Multi-arm Adaptive Randomised Trial), is the first platform trial of its kind in the UK focused on Alzheimer’s disease. Designed to evaluate multiple treatments simultaneously, the innovative approach could transform how new therapies are tested and brought to patients.
Unlike conventional clinical trials, which typically assess one drug against a placebo over several years, AD-SMART will compare multiple treatments against a single shared placebo group. Researchers will analyse results at regular intervals, allowing ineffective medicines to be removed quickly while introducing new candidates as evidence emerges.
The trial will initially investigate medicines currently used to treat type 2 diabetes and attention deficit hyperactivity disorder (ADHD), with the potential for additional therapies to be added as the programme evolves.
By using an adaptive platform design, researchers expect to reduce testing timelines by more than 50%, lower research costs and increase the proportion of participants who receive an active treatment rather than a placebo.
The programme addresses a significant unmet need within the NHS. Around 600,000 people across the UK are currently living with Alzheimer’s disease, and there are still no NHS-approved treatments capable of slowing or halting the condition’s underlying progression.
AD-SMART builds on successful adaptive trial models previously used in cancer and motor neurone disease research, bringing those innovations into dementia care for the first time at this scale.
Prime Minister Andy Burnham said:
"I know how it feels to lose a loved one to dementia and have seen first-hand the devastating impact this illness has on families.
“That's why I’m proud to see this trial being launched in the UK, so that cutting edge treatments can reach patients here as soon as possible.
“I have made dementia research a national priority. I want Britain to be the leading nation, making the breakthroughs that change people’s lives.”
Professor Paresh Malhotra, Chief Investigator and NIHR National Specialty Lead for Dementia and Neurodegeneration, said:
“For too long, Alzheimer’s research has moved at the pace of one drug, one trial, one answer, sometimes taking a decade or more before we know if we’ve found something that works.
“We are applying advances from cancer and other conditions to accelerate testing of treatments for people with Alzheimer's disease. The way AD-SMART is set up means we’re testing several treatments at the same time, and those that don’t show promise can be quickly stopped. Then we can start testing something else. That’s the best way to get effective treatments to patients as quickly as we can.”
The initiative is being led by the UK Dementia Research Institute and Alzheimer’s Research UK, in partnership with the NIHR, the Medical Research Council (MRC) and Health Data Research UK.
Recruitment is already underway at NHS trusts in London, Cambridgeshire, Surrey, Edinburgh and Southampton. Over the next 18 months, the network is expected to expand to 20 NHS sites across the UK, with more than 30 centres planned overall.
Researchers aim to recruit 1,200 participants during the first four-year phase of the programme, creating one of the largest and most ambitious Alzheimer’s treatment studies ever undertaken in the UK.
Image credit: iStock
